Department of Radiology, Karolinska University Hospital Solna, Stockholm, SE 171 76, Sweden.
EJNMMI Res. 2013 Jul 6;3(1):50. doi: 10.1186/2191-219X-3-50.
The influence of the blood glucose level on the tracer uptake of normal tissues at [18F]-2-fluoro-2-deoxy-d-glucose (FDG) positron emission tomography (PET) was retrospectively studied in examinations in clinical patients.
Five hundred examinations were evaluated in retrospect. The inclusion criteria were studies with a normal or near-normal FDG distribution. Patients who had been subjected to chemotherapy (including GSF treatment) or radiotherapy <4 weeks prior to the examination were excluded; we cannot exclude, however, that in a very few patients the available information might have been incomplete. Otherwise, patients were included regardless of concurrent diseases and/or therapy. In one evaluation, the mean standardized uptake value of the liver, spleen, lungs, peripheral blood, selected muscles and bone marrow of all 500 individuals was correlated to the blood glucose level. In another evaluation, a subgroup of 62 patients with increased blood glucose levels (≥7.0 mmol/l) was compared with another subgroup of 62 patients paired with regard to age and gender with blood glucose levels within normal range (≤6.0 mmol/l).
There was a weak positive correlation between the blood glucose level and the muscular uptake of FDG, while there was no correlation with the tracer uptake of the liver, spleen, lungs, peripheral blood or bone marrow. The patient group with increased blood glucose levels showed a slightly, but significantly, higher muscular FDG uptake compared with the matched subgroup of patients with normal blood glucose levels. When comparing the other assessed tissues/organs, there were no differences between these two patient groups.
The effect of hyperglycaemia at FDG PET on the studied normal tissues is restricted to a slightly increased muscular uptake. The effect of the blood glucose level on the blood activity at the time of examination is negligible.
本研究回顾性分析了 [18F]-2-氟-2-脱氧-d-葡萄糖（FDG）正电子发射断层扫描（PET）中血糖水平对正常组织示踪剂摄取的影响。
回顾性评估了 500 例检查。纳入标准为 FDG 分布正常或接近正常的研究。排除接受化疗（包括 GSF 治疗）或放疗<4 周的患者；但我们不能排除极少数患者的信息可能不完整。除此之外，无论患者是否合并疾病和/或治疗，均纳入本研究。在一项评估中，将 500 名个体的肝脏、脾脏、肺部、外周血、选定肌肉和骨髓的平均标准化摄取值与血糖水平相关联。在另一项评估中，将 62 例血糖升高（≥7.0mmol/L）的患者与 62 例血糖正常（≤6.0mmol/L）且年龄和性别匹配的患者进行比较。
血糖水平与 FDG 在肌肉中的摄取呈弱正相关，而与肝脏、脾脏、肺部、外周血或骨髓中的示踪剂摄取无关。血糖升高组的肌肉 FDG 摄取略高于血糖正常组，但差异无统计学意义。当比较其他评估的组织/器官时，两组患者之间无差异。
高血糖对 FDG PET 研究中正常组织的影响仅限于肌肉摄取略有增加。血糖水平对检查时血液活性的影响可以忽略不计。
